KECK KIM 4

What Happened
Kim Keck, a director of Evolent Health, was granted 41,096 restricted stock units (RSUs) on June 4, 2026. The Form 4 reports an acquisition at $0.00 per share (typical for RSU grants), so there was no cash purchase. The award was granted under the company’s 2015 Omnibus Incentive Compensation Plan.

Key Details

• Transaction date: June 4, 2026; Form 4 filed June 8, 2026 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 41,096 RSUs; acquisition price reported as $0.00.
• Vesting: RSUs vest on the earlier of June 4, 2027, and the date of the Company’s 2027 annual meeting, subject to Keck’s continued service (per footnote).
• Shares owned after transaction: Not specified in the provided excerpt.
• Plan/authority: Granted pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

Context
RSUs are a form of compensation that convert into company shares only if and when they vest; they do not represent immediate market purchases or sales and may be forfeited if the recipient leaves before vesting. Such director awards are a common component of board compensation and are informational rather than a direct market sentiment signal.